SV2006002182A - Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mip - Google Patents
Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mipInfo
- Publication number
- SV2006002182A SV2006002182A SV2005002182A SV2005002182A SV2006002182A SV 2006002182 A SV2006002182 A SV 2006002182A SV 2005002182 A SV2005002182 A SV 2005002182A SV 2005002182 A SV2005002182 A SV 2005002182A SV 2006002182 A SV2006002182 A SV 2006002182A
- Authority
- SV
- El Salvador
- Prior art keywords
- antibodies
- igf
- canceres
- igr
- sequences
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003102 growth factor Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS ANTICUERPOS CAPACES DE UNIRSE ESPECIFICAMENTE AL RECEPTOR IGF-IR DEL FACTOR DE CRECIMIENTO HUMANO SIMILAR A LA INSULINA Y/O CAPACES DE INHIBIR ESPECIFICAMENTE LA ACTIVIDAD TIROSIN-QUINASA DE DICHO IGF-IR, ESPECIFICAMENTE ANTICUERPOS MONOCIONALES DE ORIGEN MURINO, QUIMERICO O HUMANIZADO ASI, COMO LAS SECUENCIAS DE LOS AMINOACIDOS Y SECUENCIAS DE NUCLEOTIDOS QUE CODIFIQUEN ESTOS ANTICUERPOS. LA INVENCION TAMBIEN ABARCA EL USO DE ESTOS ANTICUERPOS COMO MEDICAMENTO PARA EL TRATAMIENTO PROFILACTICO Y/O TERAPEUTICO DE CANCERES QUE SOBREEXPRESEN IGF-IGR O CUALQUIER PATOLOGIA CONECTADA CON LA SOBREEXPRESION DE DICHO RECEPTOR, ASI COMO LOS PROCESOS O KITS DE DIAGNOSTICO DE ENFERMEDADES RELACIONADAS CON LA SOBREEXPRESION DE IGF-IGR. LA INVENCION FINALMENTE COMPRENDE LOS PRODUCTOS Y/O LAS COMPOSICIONES QUE ABARQUEN LOS MENCIONADOS ANTICUERPOS EN COMBINACION CON ANTICUERPOS ANTI-EGFR Y/O ANTICUERPOS ANTI-VEGF Y/O ANTICUERPOS DIRIGIDOS CONTRA OTROS FACTORES DE CRECIMIENTO INVOLUCRADOS EN LA PROGRESION DEL TUMOR O METASTASIS Y/O COMPUESTOS Y/O AGENTES ANTICANCERIGENOS O AGENTES CONJUGADOS CON TOXINAS Y SU USO PARA LA PREVENCION Y/O TRATAMIENTO DE CIERTOS CANCERES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59193204P | 2004-07-29 | 2004-07-29 | |
| FR0408379A FR2873699B1 (fr) | 2004-07-29 | 2004-07-29 | Nouveaux anticorps anti igf ir rt leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2006002182A true SV2006002182A (es) | 2006-10-04 |
Family
ID=34950307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2005002182A SV2006002182A (es) | 2004-07-29 | 2005-07-29 | Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mip |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7854930B2 (es) |
| EP (4) | EP2365006A3 (es) |
| JP (3) | JP5016487B2 (es) |
| KR (1) | KR101220635B1 (es) |
| CN (2) | CN101014625B (es) |
| AR (1) | AR050036A1 (es) |
| AU (1) | AU2005268505B2 (es) |
| BR (1) | BRPI0513890A (es) |
| CA (1) | CA2575348A1 (es) |
| CO (1) | CO5700152A1 (es) |
| FR (1) | FR2873699B1 (es) |
| GT (1) | GT200500205A (es) |
| IL (2) | IL181025A (es) |
| MX (1) | MX2007001109A (es) |
| NO (1) | NO20071093L (es) |
| NZ (2) | NZ569718A (es) |
| PA (1) | PA8640601A1 (es) |
| RU (2) | RU2406729C2 (es) |
| SV (1) | SV2006002182A (es) |
| TW (1) | TWI432451B (es) |
| WO (1) | WO2006013472A2 (es) |
| ZA (1) | ZA200700593B (es) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| JP2007535895A (ja) | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体 |
| WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
| FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| JP2008521907A (ja) | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| RU2502523C2 (ru) | 2005-06-17 | 2013-12-27 | Имклоун Элэлси | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| KR101353706B1 (ko) | 2006-02-03 | 2014-02-18 | 유니버시티 오브 워싱톤 | 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제 |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| US20090068110A1 (en) * | 2006-12-22 | 2009-03-12 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| EA200900991A1 (ru) * | 2007-02-14 | 2010-02-26 | Глаксо Груп Лимитед | Новые антитела против igf-1r |
| GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| JP5458020B2 (ja) | 2007-12-21 | 2014-04-02 | ロシュ グリクアート アクチェンゲゼルシャフト | 抗体の安定性試験 |
| EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
| US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
| MX344382B (es) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Adaptador de vial y sistema. |
| ES2981683T3 (es) | 2009-10-26 | 2024-10-10 | Hoffmann La Roche | Procedimiento para la producción de una inmunoglobulina glucosilada |
| US8444982B2 (en) * | 2009-12-04 | 2013-05-21 | The University Of Hong Kong | Anti-IGF-IR antibodies and uses thereof |
| US20110200595A1 (en) | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
| DK2575935T4 (da) | 2010-06-07 | 2023-11-27 | Amgen Inc | Anordning til indgivelse af lægemiddel |
| WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
| EP2699293B8 (en) | 2011-04-20 | 2022-07-20 | Amgen Inc. | Autoinjector apparatus |
| EP3045188B1 (en) | 2011-10-14 | 2020-12-23 | Amgen Inc. | Injector and method of assembly |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
| CA2875543A1 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| CN102830223A (zh) * | 2012-08-14 | 2012-12-19 | 四川汇宇制药有限公司 | 一种筛选治疗哺乳动物肿瘤疾病药物的方法 |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2922590B1 (en) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Drug delivery device |
| EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| CN111617347B (zh) | 2013-03-15 | 2023-09-29 | 安进公司 | 身体轮廓可调适的自动注射器装置 |
| EP2968775B1 (en) | 2013-03-15 | 2019-12-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| BR112015024282B1 (pt) | 2013-03-22 | 2022-05-17 | Amgen Inc | Injetor e método de montagem do injetor |
| WO2015035332A1 (en) | 2013-09-09 | 2015-03-12 | Canimguide Therapeutics Ab | Immune system modulators |
| EP3421066B1 (en) | 2013-10-24 | 2021-03-03 | Amgen Inc. | Injector and method of assembly |
| MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| RS61379B1 (sr) * | 2014-04-25 | 2021-02-26 | Pf Medicament | Antitelo na igf-1r i njegova upotreba kao usmerenog nosioca za lečenje kancera |
| KR102496507B1 (ko) | 2014-05-07 | 2023-02-03 | 암겐 인코포레이티드 | 충격 감소 요소들을 가진 자동 주사기 |
| KR102710533B1 (ko) | 2014-06-03 | 2024-09-26 | 암겐 인코포레이티드 | 제어 가능한 약물 전달 시스템 및 사용 방법 |
| EP3206739B1 (en) | 2014-10-14 | 2021-12-01 | Amgen Inc. | Drug injection device with visual and audio indicators |
| EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
| ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
| US10583245B2 (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
| AU2016229309B2 (en) | 2015-03-06 | 2021-12-02 | Canimguide Therapeutics Ab | Immune system modulators and compositions |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| JP7014724B2 (ja) | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリンおよびその使用 |
| ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
| MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
| JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
| EP3592403B1 (en) | 2017-03-06 | 2025-08-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
| CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
| US11986624B2 (en) | 2017-03-09 | 2024-05-21 | Amgen Inc. | Insertion mechanism for drug delivery device |
| CN114588404B (zh) | 2017-03-28 | 2024-07-09 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
| AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
| US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
| AU2018290302B2 (en) | 2017-06-23 | 2024-02-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
| JP7649105B2 (ja) | 2017-07-21 | 2025-03-19 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
| MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
| WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF |
| US12318593B2 (en) | 2017-08-09 | 2025-06-03 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
| CN111132711B (zh) | 2017-10-06 | 2022-07-01 | 安进公司 | 带有联锁组件的药物递送装置及相关组装方法 |
| EP3694578B1 (en) | 2017-10-09 | 2025-09-24 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| EP3703779A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
| WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
| MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
| SG11202002966QA (en) | 2017-11-10 | 2020-05-28 | Amgen Inc | Plungers for drug delivery devices |
| WO2019099322A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
| CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| CN112074541A (zh) | 2018-05-03 | 2020-12-11 | 上海岸迈生物科技有限公司 | Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白 |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| US12303677B2 (en) | 2018-07-24 | 2025-05-20 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
| WO2020068623A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
| IL281469B2 (en) | 2018-09-28 | 2024-08-01 | Amgen Inc | Muscle wire escapement activation assembly for a drug delivery device |
| SG11202103236YA (en) | 2018-10-02 | 2021-04-29 | Amgen Inc | Injection systems for drug delivery with internal force transmission |
| WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
| EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
| AU2019361919B2 (en) | 2018-10-15 | 2024-09-26 | Amgen Inc. | Drug delivery device having damping mechanism |
| IL281908B2 (en) | 2018-11-01 | 2025-06-01 | Amgen Inc | Drug delivery devices with partial drug delivery member retraction |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| ES3032751T3 (en) | 2019-04-24 | 2025-07-24 | Amgen Inc | Syringe sterilization verification assemblies and methods |
| MX2022002149A (es) | 2019-08-23 | 2022-03-17 | Amgen Inc | Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados. |
| AU2020337958A1 (en) | 2019-08-28 | 2022-03-17 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| BR112022006364A2 (pt) * | 2019-10-01 | 2022-06-28 | Epsilogen Ltd | Anticorpo híbrido |
| US20230381316A1 (en) * | 2020-10-20 | 2023-11-30 | The Methodist Hospital System | Psma-targeted immunotherapies for cancers |
| EP4257610A1 (en) * | 2021-01-12 | 2023-10-11 | Bioheng Therapeutics Limited | Ror1-targeting antibody and use thereof |
| CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| AU2024244149A1 (en) * | 2023-04-04 | 2025-08-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-igf1r antibodies and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| EP1261371A4 (en) * | 2000-02-25 | 2005-04-13 | Univ California | THERAPY DIRECTED ON THE MEMBRANE RECEPTOR OF ESTROGENES IN BREAST CANCER |
| SG138469A1 (en) * | 2001-01-05 | 2008-01-28 | Pfizer | Antibodies to insulin-like growth factor i receptor |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
| US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
| ES2427964T3 (es) * | 2002-01-18 | 2013-11-05 | Pierre Fabre Medicament | Nuevos anticuerpos anti-IGF-IR y sus aplicaciones |
| US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| WO2003100008A2 (en) * | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0219524D0 (en) * | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| EP1613658B1 (en) * | 2003-04-02 | 2012-03-14 | F. Hoffmann-La Roche AG | Antibodies against insulin-like growth factor i receptor and uses thereof |
| CN1835975B (zh) * | 2003-08-13 | 2012-11-21 | 辉瑞产品公司 | 经修饰的人类igf-1r抗体 |
| FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
-
2004
- 2004-07-29 FR FR0408379A patent/FR2873699B1/fr not_active Expired - Fee Related
-
2005
- 2005-07-27 EP EP11161878A patent/EP2365006A3/en not_active Withdrawn
- 2005-07-27 JP JP2007523178A patent/JP5016487B2/ja not_active Expired - Fee Related
- 2005-07-27 CN CN2005800251969A patent/CN101014625B/zh not_active Expired - Fee Related
- 2005-07-27 WO PCT/IB2005/002619 patent/WO2006013472A2/en not_active Ceased
- 2005-07-27 NZ NZ569718A patent/NZ569718A/en not_active IP Right Cessation
- 2005-07-27 BR BRPI0513890-6A patent/BRPI0513890A/pt not_active IP Right Cessation
- 2005-07-27 EP EP20110161877 patent/EP2380912A1/en not_active Withdrawn
- 2005-07-27 AU AU2005268505A patent/AU2005268505B2/en not_active Ceased
- 2005-07-27 EP EP05780625.9A patent/EP1771481B1/en not_active Expired - Lifetime
- 2005-07-27 RU RU2007107589/10A patent/RU2406729C2/ru not_active IP Right Cessation
- 2005-07-27 CA CA002575348A patent/CA2575348A1/en not_active Abandoned
- 2005-07-27 EP EP20110161875 patent/EP2365005A3/en not_active Withdrawn
- 2005-07-27 MX MX2007001109A patent/MX2007001109A/es active IP Right Grant
- 2005-07-27 KR KR1020077004904A patent/KR101220635B1/ko not_active Expired - Fee Related
- 2005-07-27 NZ NZ552821A patent/NZ552821A/en not_active IP Right Cessation
- 2005-07-27 US US11/658,739 patent/US7854930B2/en not_active Expired - Fee Related
- 2005-07-27 CN CN201310216929.3A patent/CN103951752A/zh active Pending
- 2005-07-28 GT GT200500205A patent/GT200500205A/es unknown
- 2005-07-28 TW TW094125515A patent/TWI432451B/zh not_active IP Right Cessation
- 2005-07-28 PA PA20058640601A patent/PA8640601A1/es unknown
- 2005-07-28 CO CO05074351A patent/CO5700152A1/es not_active Application Discontinuation
- 2005-07-29 SV SV2005002182A patent/SV2006002182A/es not_active Application Discontinuation
- 2005-07-29 AR ARP050103179A patent/AR050036A1/es not_active Application Discontinuation
-
2007
- 2007-01-22 ZA ZA200700593A patent/ZA200700593B/en unknown
- 2007-01-29 IL IL181025A patent/IL181025A/en not_active IP Right Cessation
- 2007-02-27 NO NO20071093A patent/NO20071093L/no not_active Application Discontinuation
-
2009
- 2009-10-21 RU RU2009138977/10A patent/RU2009138977A/ru not_active Application Discontinuation
-
2010
- 2010-12-20 US US12/973,480 patent/US8124079B2/en not_active Expired - Fee Related
-
2012
- 2012-01-18 US US13/352,976 patent/US8420085B2/en not_active Expired - Fee Related
- 2012-02-24 JP JP2012038645A patent/JP2012153692A/ja active Pending
-
2013
- 2013-12-03 IL IL229778A patent/IL229778A0/en unknown
-
2014
- 2014-03-17 JP JP2014053009A patent/JP2014193862A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2006002182A (es) | Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mip | |
| CL2009000697A1 (es) | Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras. | |
| CY1106662T1 (el) | Αντι-igf-ir αντισωματα και οι εφαρμογες τους | |
| AR063829A1 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
| EA200701250A1 (ru) | Иммуноконъюгаты против интегрина, способы и варианты применения | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| CR10493A (es) | Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata | |
| AR054175A1 (es) | Nuevos anticuerpos anti-igf-ir y usos de los mismos | |
| CY1114911T1 (el) | Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινης και [1,2,4]τριαζολο[1,5-c]πυριμιδινης και χρηση αυτων | |
| ECSP088298A (es) | Modulacion de la expresion del receptor glucocorticoide | |
| AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| CL2009000699A1 (es) | Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras. | |
| CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| MX2007010996A (es) | Nuevas composiciones de liposomas. | |
| BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
| PE20050376A1 (es) | Anticuerpos dirigidos a m-csf | |
| CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| AR071304A1 (es) | Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| TW200606162A (en) | Pyrazolopyridine derivatives | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
| WO2007117161A1 (en) | Substituted ring fused azines and their use in cancer therapy | |
| MY209484A (en) | Cpg amphiphiles and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |